To cycle or not to cycle: A critical decision in cancer

被引:1144
作者
Malumbres, M [1 ]
Barbacid, M [1 ]
机构
[1] Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid 28029, Spain
关键词
D O I
10.1038/35106065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour cells undergo uncontrolled proliferation, yet tumours most often originate from adult tissues, in which most cells are quiescent. So, the proliferative advantage of tumour cells arises from their ability to bypass quiescence. This can be due to increased mitogenic signalling and/or alterations that lower the threshold required for cell-cycle commitment. Understanding the molecular mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.
引用
收藏
页码:222 / 231
页数:10
相关论文
共 118 条
  • [1] Adams J, 1999, CANCER RES, V59, P2615
  • [2] Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks
    Adams, PD
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1471 (03): : M123 - M133
  • [3] Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation
    Alt, JR
    Cleveland, JL
    Hannink, M
    Diehl, JA
    [J]. GENES & DEVELOPMENT, 2000, 14 (24) : 3102 - 3114
  • [4] Microtubule-stabilizing agents: a growing class of important anticancer drugs
    Altmann, KH
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) : 424 - 431
  • [5] Arber N, 1997, CANCER RES, V57, P1569
  • [6] Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
    Arris, CE
    Boyle, FT
    Calvert, AH
    Curtin, NJ
    Endicott, JA
    Garman, EF
    Gibson, AE
    Golding, BT
    Grant, S
    Griffin, RJ
    Jewsbury, P
    Johnson, LN
    Lawrie, AM
    Newell, DR
    Noble, MEM
    Sausville, EA
    Schultz, R
    Yu, W
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) : 2797 - 2804
  • [7] Blagosklonny MV, 2001, CANCER RES, V61, P4301
  • [8] Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) with cyclin A-Cdk2 and cyclin D2-Cdk4
    Blain, SW
    Montalvo, E
    Massague, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (41) : 25863 - 25872
  • [9] Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E
    Bortner, DM
    Rosenberg, MP
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (01) : 453 - 459
  • [10] The cell cycle and drug discovery: the promise and the hope
    Brooks, G
    La Thangue, NB
    [J]. DRUG DISCOVERY TODAY, 1999, 4 (10) : 455 - 464